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Abstract
Background: Crimean-Congo hemorrhagic fever epidemics often occur in areas where health services are limited, and 
result in high case fatality rates. Besides intensive care, ribavirin is often recommended. A solid evidence base for the 
use of this drug will help justify assuring access to the drug in areas where epidemics are common.
Methods: We carried out a systematic review of observational and experimental studies of people with suspected or 
confirmed Crimean-Congo hemorrhagic fever that included comparisons between patients given ribavirin and those 
not. We extracted data on mortality, hospital stay, and adverse events. Risk of bias was assessed using a standard 
checklist, and data were presented in meta-analytical graphs, stratified by study design, and GRADE tables presented. 
The risk of bias was summarised using the GRADE method.
Results: 21 unique studies, including one randomised controlled trial of ribavirin, were included. Quality of the 
evidence was very low, with a Down and Black median score of 4 (maximum possible 33). Ribavirin treatment was not 
shown to be superior to no ribavirin treatment for mortality rate in a single RCT (RR: 1.13, 95%CI: 0.29 to 4.32, 136 
participants, GRADE=low quality evidence); but ribavirin was associated with reduced mortality by 44% when 
compared to no ribavirin treatment in the pooled observational studies (RR: 0.56, 95%CI: 0.35 to 0.90, 955 participants; 
GRADE=very low quality evidence). Adverse events were more common with the ribavirin patients, but no severe 
adverse events were reported. No difference in length of hospital stay was reported.
Conclusions: No clear message of benefit is available from the current data on ribavirin as observational data are 
heavily confounded, and the one trial carried out has limited power. However, ribavirin could potentially have benefits 
in this condition and these results clearly indicate a pragmatic, randomised controlled trial in the context of good 
quality supportive care, is urgently needed and ethically justified.
Background
Crimean-Congo hemorrhagic fever (CCHF) is a poten-
tially fatal viral disease. The CCHF virus is a member of
the Nairovirus genus of the Bunyaviridae family. This
genus includes other species which are pathogens in
humans such as the Dugbe virus and the Nairobi sheep
disease virus [1,2]. It possesses 3 segments of negative-
sense RNA [3,4] and an RNA dependant RNA poly-
merase packed within a lipid envelope which contains 2
viral glycoproteins [Gn and Gc]. This structure is charac-
teristic of other members of the Bunyaviridae family.
The virus is transmitted to humans through tick bites
or exposure to blood and tissues of infected animals. Dif-
ferent domestic and wild animals have been identified as
a reservoir for this virus, including cattle, sheep, goats,
hedgehogs and hares [5-8]. Numerous species of ticks can
carry the virus, however very few of them have been
implicated as vectors. The most important tick vector is
the Hyalomma spp., as the virus was isolated from it and
its geographic distribution coincides with that of the dis-
ease [9]. Another transmission route of the virus in
humans is through contact with the blood of an infected
person during the acute phase of the disease [10]. This is
especially significant among healthcare workers who may
be infected while treating CCHF patients during an out-
break [11].
One of the most important features of the virus is its
diverse geographic distribution including Africa, Asia,
Eastern Europe and the Middle East [12], making it the
most widespread tick-borne virus infecting humans. Out-
breaks have been documented in all these areas since the
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1960 s, with the most recent cases coming from Iran [13]
and Turkey [14]. In addition, climatic, environmental and
agricultural changes may affect the distribution of the
tick vector and influence the location and timing of out-
breaks.
The pathogenesis of CCHF remains elusive, mainly due
to lack of adequate animal models and laboratories with
the proper bio-safety containment level. Studies in
human patients reveal endothelial damage resulting from
either direct infection of the cells or indirect effect of viral
and host factors [15,16]. The clinical features of CCHF
are divided into four periods - incubation, pre-hemor-
rhagic, hemorrhagic, and convalescence [9]. The incuba-
tion period may vary between 2-9 days according to the
transmission route [10]. This may be followed by a sud-
den onset of signs such as fever, headache, myalgia, arth-
ralgia, abdominal pain and vomiting. Additional signs
may also appear including sore throat, conjunctivitis,
jaundice, photophobia and various sensory and mood
alterations. In severe cases, hemorrhagic manifestations
may appear as early as 3-6 days following disease onset.
Petechiae and ecchymosis of the skin and mucous mem-
branes, as well as gastrointestinal bleeding are the most
common signs at this stage, while cerebral hemorrhage
and liver necrosis reveal a more severe manifestation with
poorer prognosis [14]. Mortality rates usually range
between 5-50% [9], although numbers as high as 80%
have been reported sporadically [6].
Early diagnosis is essential in CCHF cases and is cur-
rently possible using first line molecular methods for
rapid diagnosis such as reverse transcription PCR (RT-
PCR) and real-time PCR. Serological methods such as
ELISA and immunofluorescent assays may also provide a
sensitive and specific diagnosis approximately 7 days fol-
lowing disease onset. Different cell line cultures and inoc-
u l a t i o n  o f  t h e  v i r u s  i n t o  m i c e  m a y  b e  u s e d  f o r  v i r u s
isolation [14].
Prompt supportive treatment including blood products
administration is the major current therapeutic option,
although several attempts have been made in the past to
treat patients with immunoglobulins produced from vac-
cinated horses [9] and with serum taken from convalesc-
ing CCHF patients [17]. To date, however, no clinical
trials have been reported testing the latter interventions.
More recently, the antiviral drug ribavirin - a synthetic
purine nucleoside analogue synthesized in 1972 [18] - has
revealed promising activity against the CCHF virus in
vitro [19] and in an animal model of mice [20]. Several
observational studies suggest efficacy of ribavirin in
human patients [21-23], while evidence from randomised
controlled clinical studies is lacking.
As CCHF activity appears to be increasing, particularly
in European regions [24,25], it becomes essential to
assess the effectiveness of ribavirin treatment. If results
indicate that treatment with ribavirin is promising,
efforts will need to be made to ensure its availability in
areas of the world where CCHF is present. On the other
hand, if the evidence is of poor quality and results remain
inconclusive, focus will need to be targeted on securing
better data as well as diminishing harm experienced by
the patient. At the moment, there appears to be a gap
between strongly held clinical beliefs and actual provision
of ribavirin.
Our goal was to appraise and summarise the evidence
about benefits and harms of ribavirin for treating CCHF
in humans. Secondary objectives were to evaluate the
effects of ribavirin, according to severity of disease and
number of days from onset of illness that the drug was
started, duration of ribavirin treatment, via of adminis-
tration; and to evaluate whether prophylactic use follow-
ing exposure to CCHF virus should be recommended.
Methods
Inclusion criteria
Type of studies
Randomised trials (RCTs) or observational studies com-
paring the efficacy of ribavirin with any other interven-
tion or no treatment. Case series were limited to the ones
w i t h  m o r e  t h a n  1 0  c a s e s ,  a n d  w e r e  o n l y  s u m m a r i s e d
qualitatively.
Types of participants
Children and adults of any age, with a suspected or con-
firmed diagnosis of CCHF.
Types of interventions
Ribavirin compared to any other intervention or no treat-
ment, regardless of via of administration or schedule.
Outcome measures
The primary outcome was the rate of mortality among
intervention and control groups. Secondary outcomes
were: (i) rate of mortality among those receiving ribavirin
treatment in the first 5 days from the onset of symptoms
or later than 6 days; (ii) duration of hospital stay; (iii)
improvement of disease symptoms; (iv) time to recovery
from symptoms; (v) serious adverse events that could be
fatal or lead to treatment discontinuation; (vi) any
reported adverse event; and (vii) the development of
CCHF after prophylactic use of ribavirin in health care
workers.
If information was available, all outcomes were categor-
ised according to severity of disease, number of days from
possible exposure to onset of symptoms, duration of
treatment, severity of gastrointestinal symptoms, and via
of administration.
Search strategy
We attempted to identify all relevant studies regardless of
language or publication status (published, unpublished).
Search strategies were developed from insertion untilSoares-Weiser et al. BMC Infectious Diseases 2010, 10:207
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September 2009 for the following databases: MEDLINE
http://www.nlm.nih.gov/databases/
databases_medline.html, EMBASE http://www.embase.
com/, The Cochrane Library (2009, Issue 3), Current
Controlled Trials Register, and ISI Citation Indexes at
Web of Science (ISI). In addition, the internet was
searched via general search engines, such as Google
Scholar, for relevant studies and the reference lists of the
included studies were also checked. Details of search
strategies can be found in the online material (Additional
file 1. Search Strategy).
Data collection and assessment
This systematic review followed the Cochrane Collabora-
tion Handbook [26].
Two reviewers independently inspected the abstract of
each reference identified by the search. For potentially
relevant articles, or in cases of disagreement, the full arti-
cle was obtained, independently inspected and inclusion
criteria were applied. Any disagreement was resolved
through discussion and the abstract was checked by a
third reviewer. Justifications for excluding studies from
the review were documented.
Data extraction forms were developed and piloted
independently on a small selection of studies varying in
quality. Two reviewers independently extracted informa-
tion on study population, setting, details of interven-
tion(s) used and outcomes. Data extraction was discussed
and decisions documented. Studies were identified using
the name of the first author and year in which the study
was first published. Risk of bias was assessed indepen-
dently by two reviewers using the Downs & Black check-
list for observational studies [27] and summarized using
the GRADE methodology [28]. Any disagreements were
resolved by consensus.
Statistical analyses
Statistical analyses were performed using Comprehensive
Meta-analysis (version 2). Dichotomous data was analy-
sed by calculating the risk ratio (RR) for each study and
the correspondent 95% confidence intervals. Continuous
data was analysed by calculating the standardised differ-
ence in means (SMD) for each study and the correspon-
dent 95% confidence intervals [26]. All analyses were
conducted using the random-effects model (inverse of
variance method), as we combined studies with different
methodological design and assumed that the true effect
size varied from study to study [29].
Presence of statistical heterogeneity was assessed with
the Q-test (considered significant for p < 0.10) [30] and
quantified using I-squared (I2) [31,32]. In addition, the
between-study variance (random effects) was calculated
by estimating the standard deviation of underlying effects
across studies (TAU) [26].
We planned to conduct subgroup analyses to investi-
gate whether the effects of ribavirin differs according to:
CCHF severity of symptoms, number of days from onset
of symptoms to starting the drug, duration of treatment,
severity of gastrointestinal symptoms and via of adminis-
tration. Only data on duration of treatment was provided
in three studies and analysed separately.
Results
Search results
We retrieved 1071 references from database and internet
site searches. After manually removing duplicates, two
reviewers independently screened 598 articles, and the
full report of 106 potentially relevant studies was
obtained. Of these, we included 21 studies (37 references)
and excluded 69 references (Figure 1). The primary rea-
s o n s  f o r  e x c l u d i n g  s t u d i e s  w e r e  a s  f o l l o w s :  c a s e  s e r i e s
with less than 10 cases reported (n = 20), ribavirin was
not used to treat CCHF (n = 24), not original studies (n =
13), not about CCHF (n = 8) and other reasons (n = 4).
Ultimately, two randomised trials [33,34], nine histori-
cal control [22,35-42], one case-control [43], two cohort
[44,45], two cross-sectional studies [46,47] and five case-
series with more than 10 participants [48-52] were
included in the current review. Studies were conducted in
Iran [22,34,35,46,47,49], Pakistan [42,50,52], Turkey
[33,36-41,43-45,48] and Russia [51].
Study characteristics
Participants
In one study, participants were children and adolescents
with an average age of 13.3 (SD = 4.6) years [46]; all par-
ticipants in the other studies were adults and the average
age ranged from 26 to 54 years old. The percentage of
females in the studies ranged from 22% to 68%. Eight
studies included only participants with a confirmed diag-
Figure 1 Flow chart of studies included in this review.Soares-Weiser et al. BMC Infectious Diseases 2010, 10:207
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nosed of CCHF (confirmed cases by using PCR, ELISA
and/or viral culture), five included suspected or con-
firmed cases, but reported outcomes only for those on
which the diagnosis of CCHF was confirmed and seven
studies included participants with a clinical or confirmed
diagnosis of CCHF. The sample size of the included stud-
ies varied from 8 to 283 participants. Few studies
reported the proportion of participants with co-morbidi-
ties (Additional file 2. Description of studies). A diagnosis
of CCHF was confirmed by IgM and IgG antibodies in 18
studies and no information was provided in two studies;
detection of viral antigens were used in 12 studies. Addi-
tional viral culture was used in two studies to confirm
CCHF diagnosis (Additional file 2. Description of stud-
ies).
Interventions
Except for one study, where ribavirin was administered
intravenously [37], oral ribavirin was given within a
median of three to seven days after onset of symptoms.
The dosage recommended by the World Health Organi-
zation (WHO) (30 mg/kg as an initial loading dose, then
15 mg/kg every 6 h for 4 days, and then 7.5 mg/kg every 8
h for 6 days) was used in 10 studies, different dosage was
used in three studies and seven studies did not report the
dosage of ribavirin used. Fourteen studies reported the
use of supportive therapy and blood products and this
information was not provided in six studies (Additional
file 2. Description of studies).
Outcomes
The primary outcome, mortality, was reported in 12 stud-
ies comparing ribavirin vs. no ribavirin treatment, in
three studies comparing ribavirin treatment initiated in
the first 5 days of onset or later, and in one study compar-
ing ribavirin treatment with ribavirin and immunoglobu-
lin. Adverse events (not described as serious or leading to
treatment discontinuation) were reported in four studies
and length of hospitalisation was reported in four studies.
All other outcomes were not reported.
Methodological assessment
Figure 2 summarises methodological characteristics of all
included studies. Further details are provided in the
online material (Additional file 3. Risk of bias of included
studies). Downs & Black [27] final score on the quality of
the 21 included studies ranged from 0 to 16 with a
median score of 4 (maximum possible score was 33).
Scores for each of the five factors devised by Downs &
Black [27] varied from 0 to 9 for quality of reporting
(maximum score = 11), 0 to 3 for external validity (maxi-
mum score = 3), 0 to 4 for internal validity bias (maxi-
mum score = 8), 0 to 3 for internal validity confounding
(maximum score = 6) and all studies received a 0 for
power calculation (maximum score = 5).
Effects of interventions
Mortality rate: quantitative synthesis
One RCT [33] and 11 observational studies [22,35-43,50]
provided data on rate of mortality comparing ribavirin vs.
no ribavirin treatment for CCHF (Figure 3). Ribavirin
treatment was not superior to no ribavirin treatment to
reduce the mortality rate in a single RCT (RR: 1.13,
95%CI: 0.29, 4.32, 136 participants). Ribavirin reduced
mortality by 44% when compared to no ribavirin treat-
ment in the pooled observational studies (RR: 0.56,
95%CI: 0.35, 0.90, 955 participants). Significant heteroge-
neity was observed for the pooled observational studies
(Q = 29.02, p = 0.001, I2 = 65%).
Mortality rate: qualitative synthesis
One study, published in Persian, reported results of a ran-
domised, single-blinded controlled study on which oral
ribavirin with intravenous immunoglobulin was com-
pared to oral ribavirin in only 60 CCHF patients [33].
Data is provided only for the 40 confirmed CCHF cases.
Twelve patients received ribavirin plus immunoglobulin
(intervention group) and 28 patients received only ribavi-
rin (control group) during one week; patients were fol-
Figure 2 Risk of bias assessment based on Downs & Black Check-
list.
Figure 3 Rate of mortality in patients with CCHF: ribavirin vs. no 
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lowed up for 8 weeks. Authors reported three deaths in
each group.
In an additional five studies [45,46,48,51,52] all partici-
pants received ribavirin treatment and rates of mortality
were provided:
Ayten (2008) [48] described 63 adults (mean age: 46,
SD: 16.9 years) from Eastern Turkey with a confirmed
case of CCHF. Oral ribavirin was prescribed to 46 (73%)
and a case-fatality ratio of 4.8% was reported, although it
is unclear if this was only among those receiving ribavi-
rin.
Midilli (2007) [45] investigated the genetic diversity of
the virus in 91 suspected cases of CCHF. In ten patients
CCHF was confirmed using semi-nested polymerase
chain reaction (PCR) following RT-PCR. Oral ribavirin
was prescribed to all 10 confirmed cases (dose not
reported) and no deaths were reported.
Sannikova (2007) [51] described a series of 283 adults
(age not reported) from Russia with CCHF. Oral ribavirin
was prescribed to all of them at a dose of 1000 to 1200 g
per day for two days and no deaths were reported.
Sharifi-Mood (2008) [46] described clinical and epide-
miologic features of CCHF among 34 children and ado-
lescents (mean age: 13.3, SD: 4.6 years) from a highly
endemic region in Iran. Clinical manifestations were
described as being similar to those in adults. The study
reported a case-fatality ratio of 26.5% (9 of 34).
Sheikh (2005) [52] described 135 suspected cases of
CCHF, based on a five-year hospital based case series in
the province of Balochistan in Pakistan. Eighty-three con-
firmed cases of CCHF were treated with oral ribavirin
and the study reported a case-fatality ratio was 9.6% (8 of
83).
Adverse events
One RCT [33] and three observational studies [37,39,43]
provided data on adverse events comparing ribavirin vs.
no ribavirin treatment to treat CCHF (Figure A of the
online material). None of the adverse events were
described as serious, or needed discontinuation of treat-
ment and one of the studies reported no adverse events
[40]. In the other three studies the observed adverse
events were as follows. In Koksal 2009 [33] two patients
developed serious anaemia and fatigue and these patients
had to be hospitalised for a longer period of time. Cevik
2008 [37] was the only included study evaluating intrave-
nous ribavirin in patients with severe CCHF; one patient
developed an allergic maculopapular rash that was
treated with antihistamines and two patients had nausea
and vomiting due to intravenous ribavirin, and received
symptomatic treatment. Ozkurt 2006 [43] described one
case of mild hemolytic anemia due to ribavirin that
recovered spontaneously after two days without with-
drawing the drug. Ribavirin treatment did not cause more
adverse events than no ribavirin treatment in a single
RCT (RR: 5.62, 95%CI: 0.27, 114.83, 136 participants), or
in the pooled observational studies (RR: 8.12, 95%CI:
0.97, 67.59, 85 participants, I2 = 0%).
Length of hospital stay
One RCT [33] and one observational study [36] provided
information on the average length of hospital stay com-
paring patients using ribavirin vs. no ribavirin treatment
to treat CCHF. Two other studies provided the p-value for
the difference instead of the average length of hospital
stay in days [38,43]. In order to merge the latter studies
with the other two, we converted the data into the same
effect size assuming a two-tailed p-value and indepen-
dent, unmatched groups [29]. Pooled analysis can be seen
in Figure 4. No difference was observed when those
receiving ribavirin were compared to no ribavirin treat-
ment in a single RCT (SMD: -0.21, 95%CI: -0.55, 0.12, 136
participants), or in the pooled observational studies
(SMD: -0.60, 95%CI: -1.21, 0.00, 308 participants. Signifi-
cant heterogeneity was observed for the pooled observa-
tional studies (Q = 7.74, p = 0.021, I2 = 74%).
Antibody responses following exposure to CCHF virus
One included study [44] aimed to detect antibodies
against CCHF virus in healthcare workers in one of the
largest referral tertiary-care community hospitals in Tur-
key. The sera from 75 healthcare workers were collected
one month after the last admitted hospital case (October
2003), and tested for CCHF IgM and IgG by ELISA.
Eighty three percent of the healthcare workers were at
risk of exposure to the body fluids of patients, but only
one was CCHF IgG positive. Authors reported that the
high rate of compliance to the universal precautions pro-
tected healthcare workers against CCHF infection. No
one in this study was given prophylactic ribavirin.
Sub-group analysis
Three observational studies [41,47,49] provided data
comparing ribavirin treatment starting before or after 5
days of onset of disease. No statistically significant differ-
ence was observed between groups (RR: 0.31, 95%CI: 0.08
to 1.25, 344 participants). Significant heterogeneity was
Figure 4 Length of hospital stay in patients with CCHF: ribavirin 
vs. no ribavirin treatment.S
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Table 1: Summary of findings: ribavirin vs. no ribavirin for treating patients with CCHF (population: patients with CCHF; settings: hospital based; intervention: 
ribavirin)
Outcomes Illustrative comparative risks* (95% CI) Relative effect 
(95% CI)
No of 
Participants 
(studies)
Quality of Comments
the evidence 
(GRADE)
Assumed risk Corresponding risk
Control ribavirin
Mortality (RCT)
Follow-up: mean 8 weeks
56 per 1000 63 per 1000
(16 to 242)
RR 1.13
(0.29 to 4.32)
136
(1 study)
????
low1,2
Mortality (Observational studies)
Follow-up: 1-12 months
254 per 1000 142 per 1000
(89 to 229)
RR 0.56
(0.35 to 0.9)
955
(11 studies)
????
Very low3,4,5,6
Length of Hospital stay (RCT)
Days in hospital Follow-up: mean 8 
weeks
The mean length of hospital stay (rct) 
in the control groups was
6.3 days
The mean Length of hospital stay (RCT) in the 
intervention groups was
0.21 standard deviations lower (0.55 lower to 0.12 
higher)
136
(1 study)
????
very low1,2
Length of Hospital Stay 
(Observational studies)
days in hospital Follow-up: mean 4-24 
months
The mean length of hospital stay 
(observational studies) in the control 
groups was
6.4 days
The mean Length of hospital stay (Observational 
studies) in the intervention groups was
0.60 standard deviations lower (1.21 lower to 0 
higher)
303
(3 studies)
????
Very low3,5,6,7
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk 
in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Assessment notes
1 No details of allocation concealment and method of randomisation was provided. Open label.
2 Wide confidence intervals.
3 Details of study design and population characteristics not provided in most studies.
4 Two studies (Alavi-Naimi 2006 and Nadeen 2003) were significantly more favourable to ribavirin than the other 9 included observational studies.
5 Although there was no significant lateral asymmetry on the funnel plot, and Egger's regression was not significant (intercept: 0.829, 2-tailed p-value = 0.408), we cannot completely discard 
publication bias because all studies were observational and published onl in Iran, Pakistan and Turkey.
6 Most studies used historical controls and provided little or no information about how patients were selected, whether they represent the whole population in risk or characteristics of included 
patients.
7 One study (Cevik 2008) was significantly more favourable to ribavirin than the other 2 included observational studies.Soares-Weiser et al. BMC Infectious Diseases 2010, 10:207
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observed for the pooled observational studies (Q = 13.52,
p = 0.001, I2 = 85%).
GRADE assessment
Table 1 provides an assessment of the effect estimates and
the robustness of the data using the GRADE methodol-
ogy. Ribavirin effects from observational data are of very
low quality.
Discussion and Conclusions
Evidence that ribavirin has an effect on outcome in
patients is limited. Trial data are confined to one recently
conducted randomized, placebo-controlled trial. The
confidence intervals are very wide, and so it is not possi-
ble to be confident about any effect from this data.
Observational data suggest benefit, across the 11 studies,
with confidence intervals that are significant. The point
estimate suggests a potentially large effect, but the quality
of the data is very low (see table 1), and the quality assess-
ment shows a high risk of bias. Indeed, severity of illness
is likely to confound the relationship: less severely ill
patients survived long enough after admission to receive
ribavirin, whereas the sicker patients may die sooner, and
thus be less likely to receive ribavirin. Whilst studies are
all consistent with benefit, we must guard against spuri-
ous precision from confounded association [53].
Also factors including include platelet count, white
blood cell counts, INR and gastrointestinal hemorrhage
have previously been shown to influence the outcome of
CCHF cases, and these have previously been described in
prognostic scoring systems [39]. Unfortunately, the data
from many of the trials reviewed here was limited and
severity scores were not used uniformly, therefore this
was difficult to assess. Severity criteria should also be
taken into account in any future trials looking at ribavirin
use in CCHF.
Adverse effects are more common with ribavirin than
with no treatment, but none were described as serious or
required discontinuation of treatment. However, the
n u m b e r  o f  s t u d i e s  a n d  p a t i e n t s  i n  w h o m  t h i s  w a s
reported was low.
The mortality varies considerably between the case
series and the trial. This may be a result of case mix (with
some of the older case series detecting seriously ill peo-
ple), supportive management that has been improving
over time, or simply the trial effect, with falls in mortality
in both treatment and control arms, as the trial environ-
ment generally improves care.
Limitations of the current evidence
Carrying out a randomised trial in this severe infectious
disease is commendable and the trial reported follows
good scientific principles. However, the strength of this
review would have been greatly enhanced by a more com-
plete reporting of data in the original papers. In particu-
lar, the single RCT did not report a procedure for
randomisation, a method to guarantee an adequate allo-
cation concealment and whether patients and/or health-
care workers were blinded to group assignment [33].
Furthermore, the final Downs & Black [27] quality
score for the observational studies ranged from 0 to 16
with a median score of 4 (maximum possible score was
33), showing that even if carried out adequately, the study
design has not been consistently reported.
Applicability
The patient population in the included trials was usually
young adults, with one study reporting CCHF in children.
Information concerning the risk factors of these patients
and the mechanism of exposure to CCHF virus is scarce,
as patient characteristics were rarely detailed. In addition,
all included studies contributing data for this review were
conducted in three countries (Iran, Pakistan, and Turkey),
with many other countries reported as endemic areas [54]
failing to report results of CCHF treatment or whether
treatment with ribavirin is a current practice in these
areas.
The World Health Organization has approved ribavirin
for use for CCHF and has added the drug to the essential
drug list, mainly based on its in vitro effect (reference
WHO Essential drugs submission) [55]. The drug is not
cheap, therefore if indeed it is effective, it is important
that its distribution is assured, that it is available immedi-
ately when an outbreak occurs, and health staff have clear
procedures about when and how to use the drug. This
will require substantive investment in purchase, distribu-
tion, and training in areas where health services are often
fairly basic. A clear message from research evidence of
the benefit of giving this drug, and the size of the effect,
will be of considerable help in justifying the investment
required in ensuring all patients receive this drug
promptly, and hence the need for further trials.
Implications for practice
Current research evidence is insufficient to be sure riba-
virin is of benefit in this condition. Observational data are
compatible with an effect, but are confounded and it is
not possible to rely on this data alone. The estimates from
r a n d o m i s e d  c o m p a r i s o n s  a r e  c o m p a t i b l e  w i t h  b o t h  n o
effect and a substantive benefit.
Implications for future research
There is an urgent need to rapidly establish a multi-cen-
tred, simple mortality trial of ribavirin in CCHF.
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